Abstract
Transforming growth factor beta (TGF-β) is a powerful inhibitor of cell proliferation and a potent inducer of differentiation. Resistance to TGF-β action is a characteristic of many malignancies and has been attributed to alterations of TGF-β receptors as well as disturbance of downstream transduction pathways. To analyse the TGF-β response in neuroblastoma, the expression of TGF-β1 and TGF-β type I, II and III receptor genes was investigated in 61 cancer samples by means of reverse transcription polymerase chain reaction. The specimens analysed belong to different stages, namely nine samples of stage 1, ten of stage 2, nine of stage 3 and 28 of stage 4. Moreover, five samples were of stage 4S, which represents a tumour form undergoing spontaneous regression. The results obtained show that TGF-β1 and TGF-β type I and II receptor genes appear to be almost equally expressed in neuroblastomas of all stages. Conversely, TGF-β type III receptor gene expression, which is required for an efficacious TGF-β binding and function, is strongly reduced exclusively in neuroblastomas of stages 3 and 4. These findings were directly confirmed by immunohistochemical analyses of ten neuroblastoma specimens. Our results suggest the occurrence of an altered TGF-β response in advanced neuroblastomas which might be an important mechanism for escaping growth control and for developing invasiveness. Moreover, our findings allow the proposal of a novel mechanism, namely down-regulation of TGF-β type III receptor gene expression, to avoid TGF-β inhibitory activity. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bristow RE, Baldwin RL, Yamada SD, Kore M and Karlan BY (1999) Altered expression of transforming growth factor-beta ligands and receptors in primary and recurrent ovarian carcinoma. Cancer 85: 658–668
Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M and Hedborg F (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 8: 1466–1477
Chen C, Wang X-F and Sun LZ (1997) Expression of transforming growth factor β (TGFβ) type III restores autocrine TGFβ1 activity in human breast cancer MCF-7 cells. J Biol Chem 272: 12862–12867
Coffey RL, Kost LJ, Lyons RM, Moses HL and LaRusso NF (1987) Hepatic processing of transforming factor β in the rat. J Clin Invest 80: 750–757
Cohen PS, Letterio JJ, Gaetano C, Chan J, Matsumoto K, Sporn MB and Thiele CJ (1995) Induction of transforming growth factor beta 1 and its receptors during all-trans-retinoic acid (RA) treatment of RA-responsive human neuroblastoma cell lines. Cancer Res 55: 2380–2386
Filmus J and Kerbel RS (1993) Development of resistance mechanisms to the growth-inhibitory effects of transforming growth factor-β during tumor progression. Curr Opin Oncol 5: 123–129
Filmus J, Zhao J and Buick RN (1992) Overexpression of H-ras oncogene induces resistance to the growth inhibitory action of the transforming growth factor beta-1 (TGF-β1) and alters the number of TGF-β1 receptors in rat intestinal epithelial cell clones. Oncogene 7: 521–526
Fynan TM and Reiss M (1993) Resistance to inhibition of cell growth by transforming growth factor-β and its role in oncogenesis. Crit Rev Onc 4: 493–540
Heldin CH, Miyazono K and Dijke P (1997) TGF-β signaling from cell membrane to nucleus through SMAD proteins. Nature 390: 465–471
Hougaard S, Norgaard P, Abrahamsen N, Moses HL, Spang-Thomsen M and Skovgaard Poulsen H (1999) Inactivation of the transforming growth factor beta type II receptor in human cell lung cancer cell lines. Br J Cancer 79: 10065–1011
Iolascon A, Giordani L, Moretti A, Tonini GP, Lo Cunsolo C, Mastropietro S, Borriello A and Della Ragione F (1998 a) Structural and functional analysis of cyclin dependent kinase inhibitor genes (CDKN2A, CDKN2B and CDKN2C) in neuroblastoma. Pediatr Res 43: 139–144
Iolascon A, Giordani L, Moretti A, Basso G, Borriello A and Della Ragione F (1998 b) Analysis of CDKN2A, CDKN2B, CDKN2C and cyclin D genes status in hepatoblastoma. Hepatology 27: 989–995
Iolascon A, Lo Cunsolo C, Giordani L, Cusano R, Mazzocco K, Boumgartner M, Ghisellini P, Faienza MF, Boni L, De Bernardi B, Conte M, Romeo G and Tonini GP (1998 c) Interstizial and large 1p deletion occurs in localized and disseminated neuroblastomas and predict an unfavorable outcome. Cancer Lett 130: 83–92
Johnson D, Lanahan A, Buck CR, Sehagal A, Morgan C, Mercer E, Bothwell M and Chao M (1986) Expression and structure of the human NGF receptor. Cell 47: 545–554
Kadin ME, Cavaille-Coll MW, Gertz R, Massagué J, Cheifetz S and George D (1994) Loss of receptors for transforming growth factor β in human T-cell malignancies. Proc Natl Acad Sci USA 91: 6002–6006
Kiefer MC, Stephans JC, Crawford K, Okino K and Barr PJ (1990) Ligand-affinity cloning and structure of a cell surface heparin sulfate proteoglycan that binds basic fibroblast growth factor. Proc Natl Acad Sci USA 87: 6985–6989
Kimchi A, Wang X-F, Weinberg RA, Cheifetz S and Massague J (1988) Absence of TGF-β receptors and growth inhibitory responses in retinoblastoma cells. Science 240: 196–199
Lòpez-Casillas F, Cheifetz S, Doody J, Andres JL, Lane WS and Massagué J (1991) Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-β receptor system. Cell 67: 785–795
Lòpez-Casillas F, Wrana JL and Massagué J (1993) Betaglycan presents ligand to the TGFβ signaling receptor. Cell 73: 1435–1444
Lu S-L, Akiyama Y, Saitoh K and Yuasia Y (1995) Mutations of the transforming growth factor-β type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer. Biochem Biophys Res Commun 216: 452–457
MacDonald RG, Pleffer SR, Coussens L, Tepper MA, Brocklebank CM, Mole JE, Anderson JK, Chen E, Czech MP and Ullrich A (1988) A single receptor binds both insulin-like growth factor II and mannose-6-phosphate. Science 239: 1134–1137
Maniatis T, Fritsh E and Sambrook J (1990) Molecular cloningIn: Cold Spring Harbor Laboratory, A Laboratory Manual, pp.7.6–7.22, 9.16–9.23, Cold Spring Harbor: New York
Markowitz S, Wang J, Myeroff L, Parson R, Sun L-Z, Lutterbugh J, Fan RS, Zborowska E, Vogelstein B, Brattain M and Wilson JKV (1995) Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 268: 1336–1338
Matoba H, Sagano S, Yamaguchi N and Miyachi Y (1998) Expression of transforming growth factor-beta 1 and transforming growth factor-beta type-II receptor mRNA in papillary thyroid carcinoma. Hormone Metab Res 30: 624–628
Morgan DD, Edman JC, Standring DN, Fried VA, Smith MC, Roth RA and Rutter WJ (1987) Insulin-like growth factor II receptor as a multifunctional binding protein. Nature 329: 301–307
Pinkerton CR (1993) A clinical perspective in human neuroblastoma: recent advances in clinical and genetics analysisIn: Neuroblastoma in the 1990s, Schwab M, Tonin GP and Benard J (eds), pp. 3–10, Harwood Academic: Chur. Switzerland
Polyak K (1996) Negative regulation of cell growth by TGFβ. Biochim Biophys Acta 1242: 185–199
Radeke MJ, Misko TP, Hsu C, Herzenberg LA and Shooter EM (1987) Gene transfer and molecular cloning of the rat nerve growth factor receptor. Nature 325: 593–597
Royuela M, De Miguel MP, Bethencourt FR, Sanchez-Chapado M, Fraile N and Paniagua R (1998) Transforming growth factor beta 1 and its receptor types I and II. Comparison in human prostate, benign prostatic hyperplasia and prostatic carcinoma. Growth Factors 16: 101–110
Saunders S, Jalkanen M, O'Farrell S and Bernfield M (1989) Molecular cloning of syndecan, an integral membrane proteoglycan. J Cell Biol 108: 1547–1556
Siegel SE and Sato JK (1986) NeuroblastomaIn: Oncology, Moossa AR, Robson MC and Schimpfl SC (eds), pp. 1211–1231, Williams and Wilkins: Baltimore
Sun LZ, Wu G, Willson JKV, Zborowska E, Yang J, Rajkarunanayake I, Wang J, Gentry LE, Wang XF and Brattain MG (1994) Expression of transforming growth factor β type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 269: 26449–26455
Wang X-F, Lin HY, Ng-Eaton E, Downward J, Ldish HF and Weinberg RA (1991) Expression cloning and characterization of the TGF-β type III receptor. Cell 37: 797–805
Wang J, Han W, Zbrowska E, Liang J, Wang X, Willson JKV, Sun LZ and Brattain MG (1996) Reduced expression of transforming growth factor b type I receptor contributes to the malignancy of human colon carcinoma cells. J Biol Chem 271: 17366–17371
White RL (1998) Tumor suppressor pathways. Cell 92: 591–592
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Iolascon, A., Giordani, L., Borriello, A. et al. Reduced expression of transforming growth factor-beta receptor type III in high stage neuroblastomas. Br J Cancer 82, 1171–1176 (2000). https://doi.org/10.1054/bjoc.1999.1058
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.1058
Keywords
This article is cited by
-
Retinoic acid and TGF-β signalling cooperate to overcome MYCN-induced retinoid resistance
Genome Medicine (2017)
-
Smad4 suppresses the tumorigenesis and aggressiveness of neuroblastoma through repressing the expression of heparanase
Scientific Reports (2016)
-
Single nucleotide polymorphism rs11669203 in TGFBR3L is associated with the risk of neuroblastoma in a Chinese population
Tumor Biology (2016)
-
Analysis of transforming growth factor β receptor expression and signaling in higher grade meningiomas
Journal of Neuro-Oncology (2011)